Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker

Drugmaker Eli Lilly says its oral, daily GLP-1 pill may offer similar weight loss results as weekly GLP-1 shots.

Eli Lilly said Thursday that the company's orforglipron pill can offer up to an average of 27.3 pounds of weight loss, according to results from two of its Phase 3 trials that included more than 3,000 overweight or obese adults.

"With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need."

This is a developing story. Please check back for updates.